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Abstract 
Uncontrolled developments of new blood vessels take place in cancer and many other life 
threatening diseases. Currently, RNA interference has boosted the therapeutic prospects for 
inhibiting gene expression responsible for increased and uncontrolled angiogenesis in disease 
conditions. Small interference RNA is a fast way for analysis of gene operations by masking 
their function phenotype. Angiogenesis is a complex mechanism with the involvement of many 
different protein factors. The application of siRNA enables the rapid analysis of different 
pathways and recognition of new target genes. So the Initial research on the curative effects of 
small interfering RNA in the angiogenesis process has demonstrated that this new class of 
drug takes great potential for curative innovation. There are two strategies in this regard: the 
use of “unmodified” or the use of “complexed”; “targeted and/or protected nucleic acids”.  The 
major problem for the clinical use will be to control the off-targets effects and the transient 
property of the sequence specific effect of silencing.  To tackle the targeted distribution to cells 
which is involved in the different stages of angiogenesis process will be another problem. This 
article will briefly discuss in-vitro and in-vivo “angiogenesis inhibition” related perspective in 
complex pathological conditions. 
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INTRODUCTION 
Angiogenesis is the practice of developing new blood 
capillaries from already existing blood vessels. Different 
gens products produced in specific sequence from different 
cells are responsible for this process. The RNAi acts as a 
key to activate the cell death machinery (Leulier et al., 
2006). In recent research, it provides revolutions to the 
study of gene expressions in mammals, their functions and 
role in onset of a disease. It is valid to detect and get 
access to a disease. RNAi is used for site specific 
sequence splicing or silencing, so, it is discovered effective 
with lentivirus in the process of animal transformation and 
also knockdown the gene of interest. RNAi is involved in 
formulation structure of genetic targeted drug for 
Schistosomes, by inhibiting the protein kinase C that affect 
Bl2536, which target the eggs of worm (Guidi et al., 2015).  
RNAi target the unwanted mRNAs of animals and 
plants by splicing or translational repression (Bartel et al., 
2009). These small RNAi molecules are integral part of 
different classes, which effect equilibra and conformational 
status in different ways (Shimaoka et al., 2003). It inhibits 
prostate cancer by targeting EZH2 and reduces the amount 
of EZH2 protein in cells (Varambally et al., 2002). RNAi 
inhibit the HIV-1 replication by blocking cell’s or viral 
pathway (Martinez et al., 2002). During onset of GLI-
mediated transcription, RNAi participate in final steps of 
Hedgehog pathway (Lauth et al., 2007). Betanodavirus B2 
is also an RNAi and it targets the nucleus of cell and 
accumulates in the last step of viral infection (Fenner et al., 
2006). Normally Synthetic siRNA contained 2’-O-methyl 
guanosine or uridine nucleosides in the same strand. In 
case of non-inflammatory siRNA have less than 20% 
modification (Judge et al. 2006). RNAi is involved in 
synthesis of antiviral therapeutics. Chemical modification of 
siRNA inhibits gene expression without affecting its ability 
(van Rij et al., 2006). 
                                                        
Use of RNAi 
Double stranded RNAi is widely used to silence the 
expression of genes in C. Elegans, Drosophila and even 
plants (Fire et al., 1998). It inhibits the expression of 
endogenous as well as transfected genes. The silencing 
process that it triggers in mammalian cells is gene-specific 
(Bernstein et al., 2001). This response has found its 
applications to explore the gene structure and function. It 
has ability to knock down as well as knock down the gene 
expression (Weinert et al., 1998). The transfection of 
mammalian cell or tissues with long double stranded RNAs 
become the cause of inducing antiviral interferon response 
that result in gene silencing or in some cases even cell 
death (Dorsett et al., 2004). Gene-silencing method of 
RNAi involves the sequence specific degradation of mRNA 
(Figure 1). SiRNA has now found its applications in 
therapeutics. It is regarded to have clinical potential in 
number of diseases including cancer, viral infections and 
many neurodegenerative disorders (Xu, et al., 2004). 
 
 
   
 
Fig. 1. Schematic Diagram of RNAi 
 
                                                     
Angiogenesis 
Angiogenesis is the mechanism in which new blood 
vessels are formed from pre-existing vessels. It has found 
a number of applications in pathological process including 
inflammation, muscular degeneration, tumor growth and 
formation of tumor blood vessels (Griffioen et al., 2000). 
Different inducing angiogenic proteins are involved along 
with various growth factors i.e. nPAR, VEGFs and MMPs 
expression enhanced (Figure 2). This changes the normal 
vessels to actively proliferating vessels that infiltrate the 
host tissues.  
Once tissues are injured or diseased, they continue to 
produce pro-angiogenic factors which then diffuse into 
neighboring tissues. It then binds to its specific receptors 
present on ECs surface and activate them (Suhardja et al., 
2003). This leads to the production of several enzymes that 
are secreted and dissolve basement membrane. ECs then 
proliferate and begin to migrate towards the area where 
surface proteins have produced the pro-angiogenic factors 
(Jin and Varner, 2004). ECs close and form a lumen. 
Subsequently, these small individual tubes connect with 
each other to form blood vessels that are truly functional. 
The structural support is provided to the new capillary by 
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the penetration of specialized cells (Gerhardt and 
Betsholtz, 2003). Thus, by knowing the mechanism many 
therapeutic interventions can be made possible to inhibit 
these processes. 
 
 
 
Fig. 2.  The Angiogenic process (Griffioen et al., 2000) 
                                                        
In vitro inhibition of angiogenesis 
On synthesis of DNA in angiogenesis as tool siRNA 
has been used to cut off stimulatory pathways of VEGF 
(Kranenburg et al., 2004). Due to sphingosine-kinase 
silencing VEGF unabled to stimulate Ras-GTP or 
phosphorylated ERK proteins; an important step in VEGF 
pathway and leads to initiation of DNA synthesis (Mousa 
and Mousa, 2004). Using SiRNA, the inhibition of Ets-2 
stopped amino peptidase N expression on stimulated ECs 
(Wall and Shi, 2003). As ECs trigger the capillaries 
formation, so by inhibiting Ets-2 we can inhibit 
angiogenesis. Two antiangiogenic compounds such as 
endostatin and fumagillin were analyzed by using 
differential gene expression analysis. Three genes were 
identified i.e. DOC1, TC1 and KLF4 whose expression was 
effected by both endostatin and fumagillin therapy 
(Griffioen and Molema, 2000). It showed that TC1 and 
KLF4 expression were not induced in response to 
endostatin due to the silencing of DOC1 (Grant et al., 
2004). But after fumagillin treatment, the DOC1 silencing 
did not affect TC1 and KLF4 expression induction 
(Middleton et al., 2004). These results show a role for 
DOC1 upstream from KLF4 and TC1 in angiogenic impacts 
stimulated by endostatin (Bian et al., 2004). These 
examples show the use of RNAi in indicating pathways and 
mediators which play a vital role in the angiogenic cascade 
(Sato, 2003). Figure 3 explains the transfection of cells and 
exogenously synthesis of siRNA or shRNA. 
                    
 
Fig. 3. Transfection of Cells and Exogenously 
Synthesis of siRNA or shRNA 
 
RNAi is also used to identify novel target proteins 
which are involved in the process of angiogenesis or may 
be beneficial for curative innovations (Tsopanoglou and 
Maragoudakis, 2004). The novel protein disulfide 
isomerase expressed in tumor ECs named endo-PDI. The 
normal PDI acted as a survival factor for ECs in normal 
oxygen pressure and under hypoxic conditions (Seiki et al., 
2003). The endo-PDI only did so under hypoxia which is 
determined by using siRNA (Gerhardt and Betsholtz, 
2003). The inhibition of endo-PDI cause the loss of proteins 
involved in the prevention of angiogenesis. So the endo-
PDI may be a novel antiangiogenic target (Scavelli et al., 
2004). These studies represent the impressiveness and 
ability of using RNAi to identify novel target proteins which 
can be used to inhibit angiogenesis (Sowter et al., 2004). 
 
In vivo inhibition of angiogenesis using 
siRNA 
SiRNA is a type of RNA interference. Its target is to 
decrease the angiogenesis and suppress the activity of 
tumor growth in cancer. Vasohibin 1 is a factor that works 
as a regulator to promote the angiogenesis and its activity 
is induced in endothelial cells by a stimulator known as 
vascular endothelial growth factor VEGF (Watanabe et al., 
2004). RNA Interference uses the retroviral procedures for 
the delivery of siRNA in tumor cells, systematically at low 
dosage in saline treatment result in suppressing or 
inhibiting the expression of VEGF (Brummelkamp et al, 
2002; Lewis et al., 2002).  
In in-vivo inhibition, mostky the target of siRNA is 
vasohibin 2 (stimulate the sprouting form of angiogenesis) 
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by changing the expression of its mRNA to knock down it 
efficiently. Hence, the growth of tumor would be retarded 
(Kimura  et al., 2009;, Xue et al.,2013; Takahashi et al., 
2012; Koyanagi  et al., 2013). Angiogenesis also have the 
requirement for Sphingosine 1-phosphate SP1. It is a 
growth regulator of vascular system in embryo. For its 
suppression, RNA interference uses multiplex si-RNA. It 
specifically targets the different regions of mRNA transcript 
which is over expressed in tumor cells (Chae et al., 2004). 
In case of mice tumor N2A in-vivo inhibition, mice were 
treated with siRNA injected intravenously after every 3 
days. It leads to the reduction of growth rate of tumor 
because siRNA target the mice murine VEGFR2 by 
suppressing the function of forming the new blood vessels. 
  
RNAi-based anti-angiogenesis therapeutics 
RNA interference is an endogenous mechanism for the 
powerful and precise inhibition of gene expression which 
can be applied to target specific gene in specific cell type. 
Ongoing research indicates promising and milestone result 
of this approach.  
 
siRNA targeting VEGF for cancer treatment  
Cancer growth can be halted either by activating 
exogenous/endogenous anti-angiogenesis factors or to 
introducing inhibitors to cease the pro-angiogenic factors 
activities. Ali et al. (2015) demonstrated that point mutation 
at MDM2-SNP309 from T to G may be responsible for 
hepatocellular carcinoma (HCC) in patients with HCV. 
siRNA is a powerful candidate for both of above mentioned 
properties. However, their efficiency in this regard can only 
be interpreted through in-vivo clinical trials that how they 
are introduced in host cell and and with which possible 
draw backs (Lu and Woodle, 2005). Cationic carrier VEGF-
siRNA has been reported with promising result suppressing 
angiogenesis in tumour in different research (Takei et al., 
2004). 
 
siRNA targeting VEGF to treat ocular 
neovascularization diseases 
Uncontrolled blood capillaries development in different 
diseased conditions like ocular neovascularization, age-
related macular degeneration and diabetic retinopathy 
which ultimately results in blindness. Nano particle 
associated anti-VEGF siRNA was delivered in mouse with 
promising results suppressing angiogenesis in these 
physiological conditions (Takei et al., 2004). 
  
siRNA meditated anti-angiogenesis for rheumatoid 
arthritis 
Even though no efficacy data have been reported 
using siRNA to reverse rheumatoid arthritis (RA) pathology 
in animal disease models, the potential application is very 
promising; the down regulation of RA-causing cytokines 
and their receptors and of VEGF and its signaling factors, 
either individually or with siRNAs in combination, 
represents a novel approach for the treatment of RA 
(Huang et al., 2016). 
 
CONCLUSION 
Pathways that include critical pathological conditions 
involving angiogenic cascade can be analyzed through the 
RNAi process. It also involves the detection of novel 
targeted proteins to make their use in therapeutic 
intercession. This method has broad range of applications 
because of its specificity and potential for high range of 
throughput applications. As far as therapeutic applications 
are concerned, the exceptional efficiency of RNAi and 
probability of combining siRNA for the sake of enhancing 
silencing effects are remarkable features. Since the siRNA 
have been discovered, recognized significance of RNAi 
has increased. The examination of siRNA-mediated 
retardation of angiogenesis involving animal model system 
demonstrates the brilliant future as concerned with the 
therapeutic significance of siRNA. Currently siRNA 
mediated angiogenesis has shown very promising results 
in clinical trials. Potential draw backs can be overcome and 
efficacy can be improved by in-depth understanding of 
mechanism.   The future challenges would be to direct the 
perspicacious heterogeneity of enteric coatings though 
developing therapeutic intercession for siRNA to different 
stages of angiogenesis.                                                       
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